Crenolanib
Crenolanib
Crenolanib (pronounced as kren-oh-LAN-ib) is a type of pharmaceutical drug used in the treatment of certain types of cancer. It is a potent and selective inhibitor of the platelet-derived growth factor receptor (PDGFR) that has shown promise in the treatment of acute myeloid leukemia (AML) and gastrointestinal stromal tumor (GIST).
Etymology
The name "Crenolanib" is derived from the pharmaceutical company that developed it, AROG Pharmaceuticals. The suffix "-nib" is commonly used in the names of tyrosine kinase inhibitors, which is the class of drugs that Crenolanib belongs to.
Usage
Crenolanib is used in the treatment of patients with acute myeloid leukemia (AML) that is FLT3-positive, and in patients with gastrointestinal stromal tumors (GIST) that are resistant to imatinib.
Mechanism of Action
Crenolanib works by inhibiting the activity of the platelet-derived growth factor receptor (PDGFR), which is often overactive in certain types of cancer. By blocking this receptor, Crenolanib can help to slow the growth and spread of cancer cells.
Related Terms
- Pharmaceutical drug
- Cancer
- Platelet-derived growth factor receptor
- Acute myeloid leukemia
- Gastrointestinal stromal tumor
- Tyrosine kinase inhibitors
- Imatinib
External links
- Medical encyclopedia article on Crenolanib
- Wikipedia's article - Crenolanib
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski